Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo
about
Dinosaurs and ancient civilizations: reflections on the treatment of cancerA p53 drug response signature identifies prognostic genes in high-risk neuroblastomaCombined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell linesPreclinical models for neuroblastoma: establishing a baseline for treatmentMyc proteins as therapeutic targets.G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenicWIP1 phosphatase as a potential therapeutic target in neuroblastomaMDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cellsNeuroblastoma: molecular pathogenesis and therapy.The interconnectedness of cancer cell signaling.Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achille's heel to be exploited for the therapy of MYCN-amplified neuroblastoma.Cell survival signaling in neuroblastoma.The War on Cancer rages on.Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis.Neuroblastoma treatment in the post-genomic era.Nardostachys jatamansi Root Extract Modulates the Growth of IMR-32 and SK-N-MC Neuroblastoma Cell Lines Through MYCN Mediated Regulation of MDM2 and p53.Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.Mechanisms of neuroblastoma regressionNeuroblastoma models for insights into tumorigenesis and new therapies.MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation.Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.
P2860
Q24628746-D536AFDF-A3F0-4422-82EA-A1EB012A9BF5Q28537647-B8B56DD2-6BF8-4BDA-A91F-BF1BF73FB045Q33699808-A56C55B6-8B13-4E43-87CD-3C335939E11FQ33743767-3CE3D82E-71CB-4580-98C1-A741B05753C1Q33768039-F79A1E47-1E55-4C3A-ACAB-451748FE62A3Q33895108-490810CB-12C6-4B53-BC21-E86069443E79Q33997741-ECF20595-118C-4AE8-97D8-0CBBB7B992B2Q34981973-97AE7D5E-EE06-4374-AA59-3011DEC3BE37Q35058327-B7561504-EC53-4736-9540-F7B727060DD3Q35541790-6A1A60D6-BA90-4ACA-9261-56DF2A41E7D8Q35564199-7984321A-5B7F-4D2C-83D2-C4650B20892FQ35669733-163BB133-86E3-492E-B1A5-632F5A4CDB12Q36313712-34E98BA4-0DA8-4FF1-BEDB-7E1D52C25D02Q37010166-30C874E3-E8E9-4B1B-8EBB-DB2A81FE78FDQ37478602-D7ED48C2-474E-4A5A-B67B-0AA07898DE6CQ37603053-FD7E9B7A-E3A8-4479-89E2-68493D378946Q37633731-F5EF4372-67CE-4808-8473-1AEB98375D6FQ37640821-79AE26DE-A04E-44B1-B6EC-A08F2429B694Q37940719-59A3D040-6839-4EF7-90C6-74ACE21BD8CAQ38261519-01FB368B-12F2-402A-ABE9-CD9367257AB0Q38262762-063DF172-301F-49CF-A080-DF00B45F7ECDQ38677396-1CCD7A6D-CE46-45C9-B2E0-9E2369E0C6D5Q39294214-8503614F-B75D-4590-A4FF-4CC5965215CEQ39560187-1526A458-2AFF-47E4-A767-C9ED3654EBE8Q41343291-005F2B4C-65A1-45A9-A1FC-FCC88371B5D3Q42362115-AD0D20B9-974C-48F4-A567-E8B9BAEE745CQ49233795-D447DE8C-5C24-442C-84A6-1A0607B64CCF
P2860
Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo
@en
Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
@nl
type
label
Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo
@en
Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
@nl
prefLabel
Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo
@en
Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
@nl
P2093
P2860
P356
P1433
P1476
Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo
@en
P2093
Andrew Ludwig
Eveline Barbieri
Jason M Shohet
John Hicks
Sue Burlingame
Zaowen Chen
P2860
P304
P356
10.1593/NEO.09466
P577
2009-08-01T00:00:00Z